Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor

C. Fazio, A. Agnoli, M. Casacchia, M. Reitano, S. Ruggieri, C. Barba, F. Volante

Research output: Contribution to journalArticle

Abstract

l-DOPA therapy of Parkinsonism by mouth, today universally accepted, may induce undesirable effects which can sometimes be of a certain severity. Gastrointestinal complaints and hypotension may be dependent from the dose of the drug, which can exert an irritating action on the gastric mucous, or may be due to a higher level of circulating catecholamines. Involuntary movements depend from a stimulating action on certain mesencephalic-diencephalic pathways. Pharmacologists have therefore tried to obviate these inconvenients, through the introduction of the peripheral DOPA-decarboxylase inhibitors; the administration of these drugs led to the following results in the animal: reduction of dosage consequent to a more sustained blood level of l-DOPA, reduction of side effects, possible decrease of involuntary movements. The data are obtained comparing two groups of patients: the first group (60 cases) treated with l-DOPA per os, the second group (24 cases) treated with an association of l-DOPA + decarboxylase inhibitor (Ro 8-0576, each capsule containing l-DOPA, 200 mg and Ro 4-4602, 50 mg). According to the results achieved, it can be stated that: 1. Ro 8-0576 gives a lower incidence of side effects; 2. the latency to achieve the therapeutic effect is shorter with Ro 8-0576; 3. this drug allows a greater benefit on tremor (55% with Ro 8-0576, 48% with l-DOPA only). Furthermore, the chief parkinsoniam symptoms (tremor, rigidity, akinesia) are better influenced.

Original languageEnglish
Pages (from-to)347-355
Number of pages9
JournalZeitschrift für Neurologie
Volume202
Issue number4
DOIs
Publication statusPublished - Dec 1972

Fingerprint

Parkinson Disease
Dyskinesias
Tremor
Benserazide
Pharmaceutical Preparations
Parkinsonian Disorders
Therapeutic Uses
Therapeutics
Hypotension
Catecholamines
Capsules
Mouth
Stomach
Aromatic Amino Acid Decarboxylase Inhibitors
levodopa drug combination benserazide
Incidence

Keywords

  • Decarboxylase Inhibitor
  • l-DOPA
  • Parkinson's Disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Medicine(all)

Cite this

Fazio, C., Agnoli, A., Casacchia, M., Reitano, M., Ruggieri, S., Barba, C., & Volante, F. (1972). Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor. Zeitschrift für Neurologie, 202(4), 347-355. https://doi.org/10.1007/BF00316182

Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor. / Fazio, C.; Agnoli, A.; Casacchia, M.; Reitano, M.; Ruggieri, S.; Barba, C.; Volante, F.

In: Zeitschrift für Neurologie, Vol. 202, No. 4, 12.1972, p. 347-355.

Research output: Contribution to journalArticle

Fazio, C, Agnoli, A, Casacchia, M, Reitano, M, Ruggieri, S, Barba, C & Volante, F 1972, 'Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor', Zeitschrift für Neurologie, vol. 202, no. 4, pp. 347-355. https://doi.org/10.1007/BF00316182
Fazio, C. ; Agnoli, A. ; Casacchia, M. ; Reitano, M. ; Ruggieri, S. ; Barba, C. ; Volante, F. / Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor. In: Zeitschrift für Neurologie. 1972 ; Vol. 202, No. 4. pp. 347-355.
@article{8a7e8314a607462d83acff32b3d59ccc,
title = "Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor",
abstract = "l-DOPA therapy of Parkinsonism by mouth, today universally accepted, may induce undesirable effects which can sometimes be of a certain severity. Gastrointestinal complaints and hypotension may be dependent from the dose of the drug, which can exert an irritating action on the gastric mucous, or may be due to a higher level of circulating catecholamines. Involuntary movements depend from a stimulating action on certain mesencephalic-diencephalic pathways. Pharmacologists have therefore tried to obviate these inconvenients, through the introduction of the peripheral DOPA-decarboxylase inhibitors; the administration of these drugs led to the following results in the animal: reduction of dosage consequent to a more sustained blood level of l-DOPA, reduction of side effects, possible decrease of involuntary movements. The data are obtained comparing two groups of patients: the first group (60 cases) treated with l-DOPA per os, the second group (24 cases) treated with an association of l-DOPA + decarboxylase inhibitor (Ro 8-0576, each capsule containing l-DOPA, 200 mg and Ro 4-4602, 50 mg). According to the results achieved, it can be stated that: 1. Ro 8-0576 gives a lower incidence of side effects; 2. the latency to achieve the therapeutic effect is shorter with Ro 8-0576; 3. this drug allows a greater benefit on tremor (55{\%} with Ro 8-0576, 48{\%} with l-DOPA only). Furthermore, the chief parkinsoniam symptoms (tremor, rigidity, akinesia) are better influenced.",
keywords = "Decarboxylase Inhibitor, l-DOPA, Parkinson's Disease",
author = "C. Fazio and A. Agnoli and M. Casacchia and M. Reitano and S. Ruggieri and C. Barba and F. Volante",
year = "1972",
month = "12",
doi = "10.1007/BF00316182",
language = "English",
volume = "202",
pages = "347--355",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "4",

}

TY - JOUR

T1 - Treatment of Parkinson's disease with l-DOPA and an association l-DOPA plus a DOPA decarboxylase inhibitor

AU - Fazio, C.

AU - Agnoli, A.

AU - Casacchia, M.

AU - Reitano, M.

AU - Ruggieri, S.

AU - Barba, C.

AU - Volante, F.

PY - 1972/12

Y1 - 1972/12

N2 - l-DOPA therapy of Parkinsonism by mouth, today universally accepted, may induce undesirable effects which can sometimes be of a certain severity. Gastrointestinal complaints and hypotension may be dependent from the dose of the drug, which can exert an irritating action on the gastric mucous, or may be due to a higher level of circulating catecholamines. Involuntary movements depend from a stimulating action on certain mesencephalic-diencephalic pathways. Pharmacologists have therefore tried to obviate these inconvenients, through the introduction of the peripheral DOPA-decarboxylase inhibitors; the administration of these drugs led to the following results in the animal: reduction of dosage consequent to a more sustained blood level of l-DOPA, reduction of side effects, possible decrease of involuntary movements. The data are obtained comparing two groups of patients: the first group (60 cases) treated with l-DOPA per os, the second group (24 cases) treated with an association of l-DOPA + decarboxylase inhibitor (Ro 8-0576, each capsule containing l-DOPA, 200 mg and Ro 4-4602, 50 mg). According to the results achieved, it can be stated that: 1. Ro 8-0576 gives a lower incidence of side effects; 2. the latency to achieve the therapeutic effect is shorter with Ro 8-0576; 3. this drug allows a greater benefit on tremor (55% with Ro 8-0576, 48% with l-DOPA only). Furthermore, the chief parkinsoniam symptoms (tremor, rigidity, akinesia) are better influenced.

AB - l-DOPA therapy of Parkinsonism by mouth, today universally accepted, may induce undesirable effects which can sometimes be of a certain severity. Gastrointestinal complaints and hypotension may be dependent from the dose of the drug, which can exert an irritating action on the gastric mucous, or may be due to a higher level of circulating catecholamines. Involuntary movements depend from a stimulating action on certain mesencephalic-diencephalic pathways. Pharmacologists have therefore tried to obviate these inconvenients, through the introduction of the peripheral DOPA-decarboxylase inhibitors; the administration of these drugs led to the following results in the animal: reduction of dosage consequent to a more sustained blood level of l-DOPA, reduction of side effects, possible decrease of involuntary movements. The data are obtained comparing two groups of patients: the first group (60 cases) treated with l-DOPA per os, the second group (24 cases) treated with an association of l-DOPA + decarboxylase inhibitor (Ro 8-0576, each capsule containing l-DOPA, 200 mg and Ro 4-4602, 50 mg). According to the results achieved, it can be stated that: 1. Ro 8-0576 gives a lower incidence of side effects; 2. the latency to achieve the therapeutic effect is shorter with Ro 8-0576; 3. this drug allows a greater benefit on tremor (55% with Ro 8-0576, 48% with l-DOPA only). Furthermore, the chief parkinsoniam symptoms (tremor, rigidity, akinesia) are better influenced.

KW - Decarboxylase Inhibitor

KW - l-DOPA

KW - Parkinson's Disease

UR - http://www.scopus.com/inward/record.url?scp=0015443668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015443668&partnerID=8YFLogxK

U2 - 10.1007/BF00316182

DO - 10.1007/BF00316182

M3 - Article

C2 - 4117654

AN - SCOPUS:0015443668

VL - 202

SP - 347

EP - 355

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 4

ER -